Yan Leyfman: Real-World Outcomes After First-Line Osimertinib in EGFR-Mutant NSCLC

Submitted by Anonymous on

Yan Leyfman: Real-World Outcomes After First-Line Osimertinib in EGFR-Mutant NSCLC Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared on LinkedIn:. “What happens to patients with EGFR–mutant lung cancer after first-line osimertinib stops working? The FLAURA2 trial...

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

Submitted by Anonymous on

CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced the initiation of a New Drug Application...

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 I

Submitted by Anonymous on

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission expected...

Early disease control with a biochemical response to aumolertinib after postoperative recurrence of EGFR-Mutant stage IIIA lung adenocarcinoma after icotinib, with EGFR T790M detected at recurrence: a Case Report

Submitted by Anonymous on

BackgroundEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a standard treatment for EGFR-mutant non-small cell lung cancer (NSCLC) Abstract Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a standard treatment for EGFR-mutant non-small cell lung cancer (NSCLC)....

Associations of metabolic dysfunction-associated steatotic liver disease and significant fibrosis phenotypes with glomerular hyperfiltration defined by indexed eGFR

Submitted by Anonymous on

BackgroundTo examine associations of metabolic dysfunction-associated steatotic liver disease (MASLD) and significant fibrosis with glomerular hyperfiltratio Abstract Background: To examine associations of metabolic dysfunction-associated steatotic liver disease (MASLD) and significant fibrosis with glomerular hyperfiltration (GHF) defined from indexed estimated glomerular...

Berberine and celecoxib synergistically suppress non-small cell lung cancer with EGFR/AKT/COX-2-related signaling: network pharmacology, molecular docking and experimental validation

Submitted by Anonymous on

BackgroundNon-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, and safer combination strategies with improved antitumor effi Abstract Background: Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, and safer combination strategies with improved...

Subscribe to Newsfeed